

Supplementary Table 2. Demographics, time from symptom onset to swabbing and cycle threshold values of diagnostic and study swabs for comparing nasopharyngeal (NP) and oropharyngeal (OP) swabs collected in universal transport media.

Age	Sex	Hospitalized	Symptoms Onset to Study Swabs (Days)	Symptom Onset to Diagnostic Swab (Days)	Diagnostic Swab Site	Dx Assay	Diagnostic Swab Ct			Study Assay	Study E gene Ct	
							Envelope (LDT and Seegene)/ Spike (Simplexa)	RNAdPol (LDT and Seegene)/ ORF1ab (Simplexa)	Nucleocapsid		NP swab	OP Swab
63	F	Y	7.00	0.00	OP	LDT Duplex	31.83	ND	ND	LDT Duplex	37.30	0.00
46	M	Y	28.00	19.00	OP	LDT Triplex	28.76	31.55	ND	LDT Duplex	35.90	0.00
42	F	Y	13.00	4.00	NP	LDT Triplex	18.35	21.25	ND	LDT Triplex	33.93	30.17
52	M	N	5.00	1.00	OP	LDT Duplex	28.99	ND	ND	LDT Duplex	33.82	32.25
43	F	Y	17.00	4.00	OP	LDT Triplex	22.71	25.72	ND	LDT Duplex	33.00	35.83
73	M	N	2.00	0.00	OP	Seegene	26.54	29.16	27.31	LDT Duplex	32.99	28.49
49	M	N	10.00	7.00	OP	LDT Duplex	20.82	ND	ND	LDT Duplex	32.60	29.12
68	F	Y	20.00	9.00	OP	LDT Duplex	18.39	ND	ND	LDT Triplex	32.49	32.35
83	F	Y	18.00	5.00	OP	LDT Triplex	18.62	21.8	ND	LDT Triplex	32.39	0.00
81	F	Y	17.00	8.00	OP	LDT Duplex	32.19	ND	ND	LDT Triplex	31.55	0.00
45	F	N	7.00	4.00	OP	LDT Duplex	22.65	ND	ND	LDT Duplex	31.24	32.90
86	M	Y	18.00	7.00	NP	LDT Triplex	20.32	22.95	ND	LDT Triplex	30.96	0.00
71	M	Y	9.00	4.00	NP	LDT Triplex	19.83	22.6	ND	LDT Triplex	30.93	27.48
81	F	Y	11.00	7.00	NP	LDT Triplex	21.8	24.78	ND	LDT Duplex	30.43	34.48
41	M	Y	9.00	2.00	NP	LDT Triplex	31.3	34.81	ND	LDT Triplex	30.37	23.46
73	F	N	4.00	2.00	OP	Seegene	21.16	22.16	21.95	LDT Duplex	30.35	26.88
58	M	Y	4.00	1.00	ETT	LDT Triplex	29.4	29.3	ND	LDT Triplex	28.80	0.00
64	M	N	4.00	2.00	OP	Seegene	24.53	27.22	28.24	LDT Duplex	28.16	28.65
64	F	N	6.00	2.00	OP	LDT Duplex	23.93	ND	ND	LDT Duplex	27.67	32.00
72	M	Y	11.00	6.00	Nasal	LDT Triplex	18.48	21.35	ND	LDT Triplex	27.63	35.25
33	F	N	Unknown	Unknown	OP	LDT Duplex	23.97	ND	ND	LDT Duplex	27.33	26.37
31	F	Y	29.00	21.00	NP	LDT Triplex	34.31	35.54	ND	LDT Triplex	26.62	37.02
28	F	Y	21.00	9.00	NP	LDT Triplex	19.83	22.65	ND	LDT Triplex	25.46	0.00
67	F	Y	Asymptomatic	Asymptomatic	OP	LDT Triplex	17.38	19.83	ND	LDT Triplex	23.03	16.68
33	M	Y	23.00	23.00	OP	LDT Triplex	24.45	27.3	ND	LDT Triplex	22.65	31.50
59	M	N	7.00	3.00	OP	Seegene	21.62	25.72	25.35	LDT Duplex	22.51	26.29
42	F	N	6.00	1.00	OP	LDT Duplex	19.09	ND	ND	LDT Duplex	21.87	28.45
31	F	Y	3.00	1.00	OP	LDT Duplex	21.41	ND	ND	LDT Triplex	20.28	24.70
42	M	N	3.00	0.00	OP	LDT Duplex	20.97	ND	ND	LDT Duplex	18.99	21.94
51	M	Y	11.00	1.00	NP	LDT Triplex	15.88	18.61	ND	LDT Triplex	18.38	33.95
62	M	Y	7.00	4.00	OP	LDT Triplex	28.61	30.8	ND	LDT Duplex	17.23	26.21
68	M	Y	1.00	0.00	NP	LDT Duplex	20.51	ND	ND	LDT Triplex	16.75	18.31
58	M	N	4.00	0.00	OP	LDT Duplex	30.77	ND	ND	LDT Duplex	16.48	28.06
37	F	Y	2.00	0.00	OP	LDT Duplex	25.35	ND	ND	LDT Triplex	16.43	26.62
43	F	Y	28.00	4.00	NP	LDT Triplex	Unknown	28.25	ND	LDT Triplex	0.00	32.31
58	M	Y	44.00	14.00	ETT	LDT Triplex	25.25	28.94	ND	LDT Triplex	0.00	0.00
29	M	Y	10.00	4.00	OP	LDT Triplex	28.87	30.89	ND	LDT Triplex	0.00	0.00
41	F	N	5.00	1.00	OP	LDT Duplex	32.83	ND	ND	LDT Duplex	0.00	36.16
74	M	N	6.00	5.00	OP	Seegene	22.71	24.74	25.03	LDT Duplex	0.00	35.33
32	M	N	4.00	0.00	OP	LDT Duplex	35.99	ND	ND	LDT Duplex	0.00	0.00
55	F	N	6.00	4.00	OP	LDT Duplex	27.76	ND	ND	LDT Duplex	0.00	36.24
60	M	N	5.00	0.00	OP	Seegene	22.71	24.74	25.03	LDT Duplex	0.00	36.91
72	M	Y	8.00	0.00	OP	LDT Duplex	27.73	ND	ND	LDT Duplex	0.00	0.00

Diagnostic RT-PCR testing was done either using the Alberta ProVlab lab-developed (LDT) Triplex RT-PCR targeting the Envelope (E) and RNA-dependent polymerase (RdRp) SARS-CoV-2 genes with a MS2 phage control, the LDT duplex (targeting E gene with MS2 control), Diasorin Simpexa Direct COVID-19 or Seegene Allplex nCoV 2019. Age is at the time of the study swab. ETT=endotracheal tube aspirate; Ct=cycle threshold value; ND= not detected by the assay. N/A=not available.